As we launch, our initial focus is on four critical types of cancer: lymphoma,melanoma, breast cancer, and lung cancer. However, this is merely the beginning. Our technology is inherently scalable, with the capability to replicate treatments for over 13,500diseases. Moving forward, we will continuously expand our portfolio to encompass morediseases, broadening the impact of our platform and redefining precision medicine.